Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,461 total articles
Keel Infrastructure has retooled from crypto mining into a 2.2-GW AI/HPC power pipeline. The bull case is straightforward: sign hyperscaler and enterprise leases, convert a capital-heavy development pipeline into recurring colocation revenue and justify a >$1.4B market cap. The risk is equally clear - value hinges on what the company actually monet…
PGPHF offers a headline 7%+ dividend yield that makes it attractive for income seekers, but the stock trades on a thin OTC tape, with elevated short interest and narrow technical margin for error. This trade idea outlines a mid-term buy with a tight stop, clear target near the 50-day moving average, and a set of scenarios that would change the view…
Micron is trading below short-term momentum yet sits on strong fundamentals: ~$1.03T market cap, $75 EPS, and ~$59B in free cash flow. Structural AI demand and long-term customer contracts mute fears of Chinese market flooding. This trade idea details an actionable long with entry, stop, targets, catalysts and balanced risks.
Truist (TFC) is trading near $47 with an attractive dividend and a low-teens P/E backed by $5.8B of free cash flow. A $7.7B LightStream loan sale, a shift into Treasuries, and explicit buyback capacity create clear near-term catalysts. The trade is a long with defined risk controls: entry $46.75, stop $43.50, target $53.00 over a long-term (180 tra…
Micron (MU) sits at the center of an AI-driven memory shortage that could last into the next decade. The company combines massive free cash flow, low leverage and strategic long-term customer agreements with production capacity growth in 2027–2028. I view MU as a buy from current levels with a long-term (180 trading days) horizon, a disciplined sto…
BridgeBio trades well below its 52-week high despite multiple near-term regulatory catalysts and improving commercial traction for Attruby. The company is unprofitable and levered to execution, but the current price - combined with heavy short interest and constructive technicals - creates a defined-reward trade for investors willing to tolerate bi…
UnitedHealth (UNH) delivered strong Q3 results and raised guidance, validating the recovery thesis. That rally is largely priced in: valuation metrics are rich, membership trends show cracks, and near-term catalysts favor consolidation. This trade idea outlines a mid-term short/fade with precise entry, stop and target, plus a longer-term watchlist …
Amazon's latest operational push (branded internally as Project Mercury in market chatter) aims to extract margin and demand upside through software orchestration and service packaging rather than heavy new data-center spending. With shares trading near $252.75, a moderately sized long trade targets $285 over the next 45 trading days, balancing ups…
T-Mobile combines scale, predictable cash flow and a low-risk path to expanding indoor and rural internet coverage. Recent SpaceX spectrum moves rattled the sector, but for patient investors who want exposure to expanding broadband and mobile convergence, T-Mobile's valuation, margins and free cash flow make it a cleaner trade than betting on Starl…
EchoStar's operating metrics remain weak - negative EPS, negative free cash flow and meaningful leverage - but a wave of spectrum transactions involving SpaceX (including previously acquired 2 GHz spectrum linked to EchoStar) creates a credible pathway to crystallize value in the asset base. This trade idea targets a tactical long over a mid-term 4…
Bayer is showing signs of a credible turnaround across Crop Science and Pharmaceuticals, driven by margin recovery and disciplined cost management. Legal overhangs have eased but gross leverage remains a key constraint. This trade buys into operational momentum with a clearly defined stop to protect against balance-sheet setbacks.
IBEX has pivoted beyond low-margin contact center services into AI-driven customer experience (CX) products. With recent beat-and-raise results, a lean balance sheet and an EV/EBITDA of ~7.7x, the stock looks set up for multiple expansion if management executes on its $700-715M fiscal 2027 revenue target and AI adoption continues. This trade sets a…
Reddit has become the go-to raw feed for ad targeting signals and AI training data. With 50%+ revenue growth expectations and a clean balance sheet, the market is asking for execution. This trade idea takes a tactical long ahead of the October 29, 2026 earnings print with a defined entry, stop and target that balances upside from positive catalysts…
Palantir pulled back after an AI software rotation, but fundamentals argue this is not a hype stock - it runs mission-critical systems for governments and enterprises, generates meaningful free cash flow, and sits on a fortress-like balance sheet. This trade targets a rebound to $210 in the next 45 trading days and a run to $260 over the next 180 t…
Amadeus (AMADY) faces headline risk from AI-driven booking tools that aim to bypass traditional distribution fees. That threat can pressure pricing and multiples, but the company's deep integration across airlines, airports and hospitality - plus a $26.15B market cap, 2.1% yield and mid-teens P/E - make it a reasonable mid-term long with tight risk…
McDonald's (MCD) looks like an attractive long trade right now. The company's asset-light, franchise-driven model produces steady cash flow and high margins, and recent operational initiatives (menu optimization, digital penetration and delivery) support better traffic and mix. This trade targets capital appreciation over the next 180 trading days …
Cerebras (CBRS) has been sold aggressively into fears around margin pressure and customer concentration. Fundamentals and order momentum argue the sell-off is overdone. This is a pragmatic, actionable long: entry $127.24, stop $115.00, target $190.00 over a mid-term (45 trading days) horizon.
Broadcom's pullback has pushed the stock below many short-term technical anchors, but the company's cash flow, margins, and AI exposure make this an attractive tactical long. This trade idea lays out an entry at the current price, clear stops, and staged targets across three horizons while flagging the operational and macro risks that could derail …
Broadcom (AVGO) has slid from a $495 52-week high to roughly $330 after a sharp sector rotation. The sell-off looks like an overreaction to headline risk given Broadcom's strong cash generation, exposure to hyperscaler AI spending, and modest short interest. This is a tactical long: entry $330.30, stop $298.00, target $395.00 over a mid-term window…
MSCI is trading near $569 after a pullback that brings its earnings multiple to roughly 30x while consensus expects double-digit revenue and EPS growth for Q3. The business is highly recurring and cash generative; this trade targets a recovery toward prior highs with a defined stop in case the print disappoints.
Adyen is shifting from a pure payments processor into a platform-led checkout business that captures more fees, sticky merchants, and product-led expansion. This trade idea outlines a long position with explicit entry, stop, and target, explains the fundamental drivers, lays out catalysts, and highlights the key risks that would invalidate the thes…
Oruka Therapeutics (ORKA) is a clinical-stage biotech that looks mispriced given Phase 2 durability data for ORKA-001 and a commercial build underway. The market for biologic psoriasis drugs is polarizing into frequent-dosing incumbents and a few ultra-long-duration challengers; ORKA-001 sits at the high-return end of that barbell. This trade idea …
Micron (MU) recently closed back below key intraday support and is trading under its short- and medium-term moving averages. That breakdown presents a tactical opportunity: wait for a volume-backed reclaim of near-term resistance, then buy into strength with a tight stop and a mid-term target near the next logical resistance band. The company’s mas…
Dexcom's G7 15-day sensor materially reduces per-day sensor cost and improves gross margins. With 2025 revenue at $4.66B, FCF generation of ~$1.4B, and margins expanding, the stock looks well positioned to benefit as CGM adoption accelerates in non-insulin Type 2 diabetes. This trade idea is a directional long with entry at $86.04, stop at $80.00, …
<p>Grab is trading at $2.94 and priced for a slow recovery. We think that underappreciates the company's path to stronger adjusted EBITDA and expanding financial-services monetization across Southeast Asia. This is a long-term trade (180 trading days) to capture re-rating as execution on Atome integration and AI infrastructure partnerships drive re…
